Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study findsChemotherapy linked to immune system changes in ovarian cancer patients

Frontiers in Medicine Published April 8, 2026 DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note: Observational HGSOC data link chemotherapy to NK cell modulation and ligand-PFS association.

An observational cohort study analyzed clinical specimens from 107 patients with high-grade serous ovarian cancer (HGSOC) undergoing surgery and chemotherapy, and 50 age- and gender-matched healthy participants. The cohort included 33 chemo-naïve patients undergoing primary debulking surgery (PDS), 57 chemotherapy-treated patients undergoing interval debulking surgery (IDS), and 17 patients in the IDS group followed during chemotherapy cycles. The study aimed to characterize chemotherapy-induced immune modulation on natural killer (NK) cell receptors and ligands.

Compared to the chemo-naïve surgical cohort, the chemotherapy-treated surgical cohort showed increased surface MICA expression on EpCAM+ cells (p = 0.0466). Natural Cytotoxicity Receptors (NCRs) on NK cells, which were downregulated in chemo-naïve patients, normalized to a level comparable to healthy controls after chemotherapy. NKG2D+ immune cells were reduced in both surgical cohorts compared to healthy controls. Proinflammatory cytokines IL-2 and TNF-α were reduced in the chemotherapy-treated cohort (IL-2: p = 0.0001, TNF-α: p = 0.0442), while intracellular levels of dual perforin and granzyme were elevated. In a secondary analysis, high surface expressions of HLA-E, MIC-B, and LLT-1 ligands were associated with improved progression-free survival.

Safety and tolerability data were not reported. The study is limited by its observational design, which shows associations but cannot establish causation. The sample size is modest, and multiple comparisons were made without reported effect sizes or absolute numbers for most outcomes. Funding and conflicts of interest were not reported. The findings may offer mechanistic insights for future research into combination immunotherapies in HGSOC but do not demonstrate clinical efficacy or a direct survival benefit from the observed immune changes.

Researchers conducted a small observational study to see how chemotherapy affects the immune system in people with high-grade serous ovarian cancer. They compared immune cells from 33 patients who had surgery before chemotherapy, 57 patients who had chemotherapy before surgery, and 50 healthy people. A smaller group of 17 patients was followed during their chemotherapy cycles.

The study found that chemotherapy was linked to changes in certain immune system markers. Some markers on natural killer (NK) immune cells, which were lower in cancer patients before treatment, returned to levels more like those in healthy people after chemotherapy. The treatment was also linked to increased levels of some proteins that help immune cells kill cancer cells. In a separate finding, higher levels of three specific proteins on tumor cells were linked to longer periods without the cancer getting worse.

It is important to be careful with these results. This was an observational study, which means it can only show links, not prove that chemotherapy caused these changes or that the changes led to better survival. The study was small and did not report on side effects or how well patients tolerated treatment. The findings are early and need to be confirmed in much larger studies. For now, this research offers a clue about how chemotherapy might interact with the immune system in ovarian cancer, which could help guide future studies on combination treatments.

What this means for you:

Early study finds chemotherapy linked to immune changes in ovarian cancer; more research is needed.

Study Details

Study typeCohort

EvidenceLevel 3

PublishedMar 2026

View Original Abstract ↓

IntroductionCombination approaches are being explored to improve immunotherapy efficacy, yet the immunomodulatory effects of chemotherapy on NK cell receptors and their ligands remain unexplored in high-grade serous ovarian cancer (HGSOC). Therefore, understanding chemotherapy-induced immune modulation is essential in HGSOC.MethodsImmune profiling was conducted on clinical specimens from 33 chemo-naïve patients undergoing primary debulking surgery (PDS), 57 chemotherapy-treated patients undergoing interval debulking surgery (IDS), and 17 patients in the IDS group were followed during chemotherapy cycles. Immune profiling was carried out using flow cytometry, Procartaplex immunoassay, and ELISA. Blood samples were collected from 50 age- and gender-matched healthy participants for comparison.ResultsPrimary investigation on follow-up patients reveals chemotherapy-mediated immune modulation on NK cell subsets. This was further validated in the chemo-treated surgical cohort. The Natural Cytotoxicity Receptors (NCRs) were downregulated on NK cells in chemo-naïve surgical cohorts. The NCR group of receptors was normalized to a level comparable to that in healthy controls in the chemotherapy-treated surgical cohort, due to reduced soluble ligands. Surface MICA expression was also increased (p = 0.0466) on EpCAM+ cells in the chemo-treated surgical cohort compared to the chemo-naïve surgical cohort, while NKG2D+ immune cells were reduced in both surgical cohorts compared to healthy controls. Moreover, proinflammatory cytokines IL-2 (p = 0.0001) and TNF-α (p = 0.0442) were reduced in the chemotherapy-treated surgical cohort, while intracellular levels of dual perforin and granzyme were elevated in the chemo-treated group, which may enhance cytolytic potential. High surface expressions of HLA-E, MIC-B, and LLT-1 ligands were associated with improved progression-free survival.ConclusionsOur findings highlight the broad immunomodulatory effects of chemotherapy on NK cell receptors, ligands, and cytokines, which may offer insights for combination therapies in HGSOC.

Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study findsChemotherapy linked to immune system changes in ovarian cancer patients

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Chemotherapy in HGSOC patients modulates NK cell receptors and ligands, observational study findsChemotherapy linked to immune system changes in ovarian cancer patients

More on High Grade Serous Ovarian Cancer

Study Details

Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma

New Asthma Drug Cuts Attacks Without Recent Crisis

Clinical research that matters. Delivered to your inbox.

Related in Allergy & Immunology

From Other Specialties